Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 21, 2026
Primary Event: Announcement of updated interim clinical data for ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic colorectal cancer (CRC).
Key Financial Metrics
This filing is a current report regarding clinical developments and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details significant clinical updates for ozekibart in a heavily pretreated CRC population (cutoff date: April 10, 2026). Key metrics from the Phase 1/2 study include:
- Population: 45 evaluable patients; ~70% received therapy as fourth-line; 80% previously progressed on irinotecan-based regimens.
- Objective Response Rate (ORR): 20% (per RECIST v1.1), compared to a historical standard of care ORR of 1-6%. Nearly half of responses were durable (>6 months).
- Progression-Free Survival (PFS): Median PFS of 5.5 months. 42% of patients remained progression-free at the 6-month landmark.
- Disease Control Rate (DCR): 87% (partial responses and stable disease).
- Safety: Manageable profile with common adverse events (diarrhea, fatigue, nausea) largely Grade 1 or 2. No significant liver toxicity observed despite 68% of patients having liver metastases.
Guidance, Outlook, and Risks
Regulatory and Development Plans:
- First-Line CRC: Plans to meet with the FDA in the second half of 2026 to discuss initiating a registrational trial.
- Accelerated Pathways: Plans to discuss potential accelerated regulatory pathways for fourth-line CRC and refractory Ewing sarcoma.
- BLA Submission: Submitted a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma in April 2026.
Risks and Contingencies:
- Interim data may not reflect final results or data from later trials.
- Uncertainty regarding the initiation, timing, and results of future clinical trials.
- Potential for unexpected adverse side effects or inadequate efficacy.
- Regulatory approvals are not guaranteed, and accelerated pathways may not be available.
Investor Verification Checklist
- Verify the final analysis of the Phase 1/2 CRC study data to confirm the 20% ORR and 5.5-month median PFS.
- Monitor the outcome of the planned FDA meeting in H2 2026 regarding the first-line registrational trial design.
- Track the status of the BLA submission for conventional chondrosarcoma submitted in April 2026.
- Review the Company's cash position in subsequent 10-Q filings, as this 8-K does not disclose liquidity levels required to fund upcoming trials.